Ezaladcigene resoparvovec

瑞艾西基

Report date: 2024/08/21 20:00:59

Base Information

Drug NameEzaladcigene resoparvovec
Drug Alias NameAV-hAADC-2(Neurocrine Biosciences)AAV-AADC gene therapy(Neurocrine Biosciences)AAV-hAADC gene therapy(Neurocrine Biosciences)AAV2-hAADC(Neurocrine Biosciences)AAV-AADC(Neurocrine Biosciences) +[10] 
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector
Mechanisms of ActionDDC gene transference
TargetsAromatic-L-amino-acid decarboxylase
Therapy Area/IndicationsAromatic amino acid decarboxylase deficiencyParkinson Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of CaliforniaVoyager Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of California San FranciscoThe Ohio State University
Inactive CompaniesVoyager Therapeutics IncNeurocrine Biosciences Inc
Active IndicationsAromatic amino acid decarboxylase deficiencyParkinson Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A